medigraphic.com
ISSN 1561-2929 (Print)

2016, Number 1

<< Back Next >>

RCAN 2016; 26 (1)

On the metabolism of homocysteine. Implications for nutrition

Rosabal NEL

Language: Spanish
References: 70
Page: 157-171
PDF size: 424.20 Kb.


ABSTRACT

Homocysteine (Hcy) is a risk factor for endothelial damage and ischemic disease independent in its behavior from other traditional ones such as serum lipids. Homocysteine originates from metionine within alternate metabolic routes of transsulfuration and remethylation. Defficient folate states represent an important cause of hyperhomocisteinemia. Hyperhomocisteinemia is associated with increased incidence of myocardial infarction, vascular (arterial | venous) thrombosis, and other territorial | systemic ischemic accidents. Supplementation with folic acid is the main nutritional intervention in the hyperhomocisteinemia states. Consumption of folic acid “megadoses” might result in reduction of Hcy serum levels without affecting the rate of DNA methylation: an event implicated in thrombotic damage. Evidences accumulated up to this day are not conclusive regarding the benefits of folic acid supplementation upon incidence of ischemic and/or thrombotic episodes.


REFERENCES

  1. du Vigneaud V. Interrelationships between choline and other methylated compounds. Biol Symposia 1941;5(234): 1942-3.

  2. Carson NA, Cusworth DC, Dent CE, Field CMB, Neill DW, Westall RG. Homocystinuria: A new inborn error of metabolism associated with mental deficiency. Arch Dis Child 1963; 38(201):425.

  3. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31-62.

  4. Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA; et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Int Med 1999;159:1077-80.

  5. Blanco Vaca F. Hiperhomocisteinemia asociada a múltiples enfermedades, desde la aterotrombosis al Alzheimer: ¿Casualidad o causalidad? Clin Invest Arterioscl 2003;15:69-72.

  6. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002:288:2015-22.

  7. Chichizola C, Ludueña B, Mastandrea C, Sánchez H. El valor diagnóstico de la homocisteína. Utilidad clínica. Rev Arg Endocrinol Metab 2003;40:32-42.

  8. Malinow MR. Homocysteine and arterial occlusive diseases. J Intern Med 2014;236:603-17.

  9. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ. 2002;325:1202.

  10. González Juanatey JR, Cordero A, Vitale GC, González Timón B, Mazón P, Bertomeu V. Magnitude and characteristics of residual lipid risk in patients with a history of coronary revascularization: The ICP-Bypass Study. Rev Esp Cardiol 2011;64:862-8.

  11. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: Pathogenesis and therapeutic approach. Cardiovasc Pathol 2004;13:125-38.

  12. Castro R, Rivera I, Blom HJ, Jakobs C. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: An overview. J Inherit Metab Dis 2006;29:3-20.

  13. Cacciari E, Salardi S. Clinical and laboratory features of homocystinuria. Haemostasis 1989;19(Suppl 1):S10-S13.

  14. Suárez García JF, Gómez Cerezo JJ, Ríos Blanco FJ, Barbado Hernández JJ, Vázquez Rodríguez. La homocisteína. ¿El factor de riesgo cardiovascular del próximo milenio? Anales Medicina Interna [España] 2001;18:8;211-7.

  15. Stevens AP, Dettmer K, Kirovski G, Samejima K, Hellerbrand C, Bosserhoff AK; et al. Quantification of intermediates of the methionine and polyamine metabolism by liquid chromatography-tandem mass spectrometry in cultured tumor cells and liver biopsies. J Chromatogr A 2010; 1217:3282-8.

  16. Quesada Araya A, Bolaños Cubillo A. Hiperhomocisteinemia y enfermedad arterial coronaria. Rev Médica Costa Rica Centroamérica 2012;69(600):83-90.

  17. Greenlund KJ, Srinivasan SR, Xu JH, Dalferes E, Myers L, Pickoff A, Berenson GS. Plasma homocysteine distribution and its association with parental history of coronary artery disease in black and white children: The Bogalusa Heart Study. Circulation 1999; 99:2144-9.

  18. Stehouwer CD, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJ, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men. A 10-year follow-up. Arterioscl Thromb Vasc Biol 1998;18:1895-1901.

  19. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999;281:1817-21.

  20. Kelly PJ, Furie KL, Kistler JP, Barron M, Picard EH, Mandell R, Shih VE. Stroke in young patients with hyperhomocysteinemia due to cystathionine beta-synthase deficiency. Neurology 2003;60:275-9.

  21. Papoutsakis C, Manios Y, Magkos F, Papaconstantinou E, Schulpis KH, Zampelas A; et al. Effect of the methylene-tetrahydro-folate-reductase (MTHFR 677C>T) polymorphism on plasma homocysteine concentrations in healthy children is influenced by consumption of folate-fortified foods. J Nutr 2010;26:969-74.

  22. Refsum H, Fiskerstrand T, Guttormsen AB, Ueland PM. Assessment of homocysteine status. J Inherited Metab Dis 1997;20:286-94.

  23. Haagsma CJ, Blom HJ, van Riel PL, van’t Hof MA, Giesendorf BA, van Oppenraaij-Emmerzaal D, van de Putte LB. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58:79-84.

  24. Ono H, Sakamoto A, Eguchi T, Fujita N, Nomura S, Ueda H; et al. Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants. Metabolism 1997; 46:959-62.

  25. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 1988;81:466-73.

  26. Mills JL, Lee YJ, Conley MR, Kirke PN, McPartlin JM, Weir DG, Scott JM. Homocysteine metabolism in pregnancies complicated by neural-tube defects. The Lancet 1995;345(8943): 149-51.

  27. Pizzolo F, Blom HJ, Choi SW, Girelli D, Guarini P, Martinelli N; et al. Folic acid effects on S-adenosylmethionine, Sadenosylhomocysteine, and DNA methylation in patients with intermediate hyperhomocysteinemia. J Am Coll Nutr 2011;30:11-8.

  28. Basten GP, Duthie SJ, Pirie L, Vaughan N, Hill MH, Powers HJ. Sensitivity of markers of DNA stability and DNA repair activity to folate supplementation in healthy volunteers. Brit J Cancer 2006;94:1942-7.

  29. Klee GG. Cobalamin and folate evaluation: Measurement of methylmalonic acid and homocysteine vs vitamin B12 and folate. Clin Chem 2000; 46:1277-83.

  30. Brattstrom L. Vitamins as homocysteinelowering agents. J Nutr 1996;126(4 Suppl):S1276-S1283.

  31. Verhoef P, Stampfer MJ, Buring JF, Gaziano JM, Allen RH, Stabler SP; et al. Homocysteine metabolism and risk of myocardial infarction: Relation with vitamins B6, B12, and folate. Am J Epidemiol 1996;143:845-59.

  32. Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993;40:230-5.

  33. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Int Med 2004; 140:9-17.

  34. McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-5.

  35. McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis 1975; 22:215-27.

  36. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. New Engl J Med 1997;337: 230-7.

  37. Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24:704-9.

  38. Sundström J, Sullivan L, D’Agostino RB, Jacques PF, Selhub J, Rosenberg IH; et al. Plasma homocysteine, hypertension incidence, and blood pressure tracking the Framingham Heart Study. Hypertension 2003;42:1100-5.

  39. Schalinske KL. Interrelationship between diabetes and homocysteine metabolism: Hormonal regulation of cystathionine [beta]-synthase. Nutr Rev 2003;61: 136-52.

  40. Catargi B, Parrot-Roulaud F, Cochet C, Ducassou D, Roger P, Tabarin A. Homocysteine, hypothyroidism, and effect of thyroid hormone replacement. Thyroid 1999;9:1163-6.

  41. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. The Lancet 1996; 348(9035):1120-4.

  42. Roubenoff R, Dellaripa P, Nadeau MR, Abad LW, Muldoon BA, Selhub J, Rosenberg IH. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheumatism 1997;40:718-2.

  43. Malerba M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton PG, Girolomoni G. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Brit J Dermatol 2006;155:1165-9.

  44. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999;281:1817-21.

  45. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997;95:1777-82.

  46. Lentz SR. Mechanisms of homocysteineinduced atherothrombosis. J Thrombosis Haemostasis 2005;3:1646-54.

  47. Thambyrajah J, Townend JN. Homocysteine and atherothrombosis- Mechanisms for injury. Eur Heart J 2000;21:967-74.

  48. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.

  49. Okumura KI, Aso Y. High plasma homocysteine concentrations are associated with plasma concentrations of thrombomodulin in patients with type 2 diabetes and link diabetic nephropathy to macroangiopathy. Metabolism 2003; 52:1517-22.

  50. Harpel PC, Zhang X, Borth W. Homocysteine and hemostasis: Pathogenetic mechanisms predisposing to thrombosis. J Nutr 1996;126(4 Suppl):S1285-S1290.

  51. Bienvenu T, Ankri A, Chadefaux B, Montalescot G, Kamoun P. Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters. Thrombosis Res 1993;70:123-9.

  52. Harpel PC. Homocysteine, atherogenesis and thrombosis. Fibrinol Proteol 1997; 11:77-80.

  53. Gerhard GT, Duell PB. Homocysteine and atherosclerosis. Cur Opinion Lipidol 1999;10:417-28.

  54. Coppola A, Davi G, De Stefano V, Mancini FP, Cerbone A, Di Minno G. Homocysteine, coagulation, platelet function, and thrombosis. Sem Thromb Hemost 2000;26:243-54.

  55. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Nat Acad Sci 1994;91:6369-73.

  56. Goldstein LB. Novel risk factors for stroke: Homocysteine, inflammation, and infection. Cur Atherosclerosis Rep 2000; 2:110-4.

  57. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway role of asymmetric dimethylarginine. Circulation 2001; 104:2569-75.

  58. Selhub JM, Miller JW. The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by Sadenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992;55:131-8.

  59. Kredich NM, Hershfield MS. Perturbations in S-adenosylhomocysteine and S-adenosylmethionine metabolism: Effects on transmethylation. Advances Enzyme Regul 1980;18:181-91.

  60. Troesch B, Hoeft B, McBurney M, Eggersdorfer M, Weber P. Dietary surveys indicate vitamin intakes below recommendations are common in representative Western countries. Brit J Nutr 2012;108:692-8.

  61. Trumbo PR, Yates AA, Schlicker-Renfro S, Suitor C. Dietary Reference Intakes: Revised nutritional equivalents for folate, vitamin E and provitamin A carotenoids. J Food Comp Analysis 2003;16:379-82.

  62. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. Brit Med J 1998; 316(7135):894-8.

  63. Homocysteine Lowering Trialists’Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: A metaanalysis of the randomized trials. Am J Clin Nutr 2005;82:806-12.

  64. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354:1567-77.

  65. Clarke R, Armitage J. Vitamin supplements and cardiovascular risk: Review of the randomized trials of homocysteine-lowering vitamin supplements. Sem Thromb Hemost 2000;26:341-8.

  66. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: A meta-analysis of randomized controlled trials. JAMA 2006;296:2720-6.

  67. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y; et al. Efficacy of folic acid supplementation in stroke prevention: A meta-analysis. The Lancet 2007; 369(9576):1876-82.

  68. Pizzolo F, Blom HJ, Choi SW, Girelli D, Guarini P, Martinelli N; et al. Folic acid effects on S-adenosylmethionine, Sadenosylhomocysteine, and DNA methylation in patients with intermediate hyperhomocysteinemia. J Am Coll Nutr 2011;30:11-8.

  69. Martí-Carvajal AJ, Solà I, Lathyris D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2015;1:CD006612. doi: 10.1002/14651858.CD006612.pub4.

  70. Doshi SN, McDowell IF, Moat SJ, Payne N, Durrant HJ, Lewis MJ, Goodfellow J. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002;105:22-6.




2020     |     www.medigraphic.com